Bioeconomy Capital is a biotechnology investment firm. The primary focus of Bioeconomy Captial is the industrialization of early stage biotechnology companies operating within the bioeconomy making products such as materials, chemicals, and enzymes.
Completion of Bioeconomy Fund 1
On January 1, 2017 Bioeconomy Capital completed their bioeconomy fund 1 investment portfolio of early stage biotechnology companies. Bioeconomy Capital invested a total of $8.3 million into 6 early stage biotechnology companies — Zymergen, Riffyn, Rooster Bio, Synthace, Arzeda, and Bellwether Bio.
Investments
Timeline
Completion of Bioeconomy Fund 1
On January 1, 2017 Bioeconomy Capital completed their bioeconomy fund 1 investment portfolio of early stage biotechnology companies. Bioeconomy Capital invested a total of $8.3 million into 6 early stage biotechnology companies — Zymergen, Riffyn, Rooster Bio, Synthace, Arzeda, and Bellwether Bio.
Funded Companies
SynthaceSynthace is a software company based out of London, UK building automation software that gives biologists the ability to control and analyze the performance of lab hardware.
London
ArzedaArzeda is a biotechnology and software company designing custom microorganisms for industrial applications through computational enzyme design, protein optimization, and metabolic engineering.
SeattlePeople
Rik Wehbring
Founder & managing director (San Francisco)
Rob Carlson
Founder & managing director (Seattle)
Tim Fell
Employee
Tim Gardner
Employee
Further reading
GBS 2018: Bioeconomy leaders foster shift to sustainable industry production
BIOCOM AG
News article
Xconomy: Seattle Area Had a Middling 2017 for Venture Investment, Fundraising
Benjamin Romano
News article
Documentaries, videos and podcasts
Auto-extract from URL...
Companies
References
Bioeconomy Capital
Investor
CompanyCompany attributes
Biotechnology
Automation
Synthetic biology
San Francisco
Rob CarlsonCategories
Related Topics
Contributors
- 1
Dawson Sewell
Seeking to explain science and technology through simple writing. - 2
Alex Dean
Healthcare Research Analyst @ Veradigm | Masters in Biostatistics/Epidemiology: UC Berkeley | BA in Biology: Wesleyan University - 3
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME - 4
Mevludin Mešanović
Bachelor of Electrical Engineering - 5
Jude Gomila
Founder and CEO of Golden, Entrepreneur. Investor in 200+ companies. Cantabrigian (Gonville and Caius). Interested in the universe. - 6
Will Suter
Student at the University of Notre Dame looking to expand my knowledge in topics that pique my interest. - 7
Carla Faraguna
Golden People and Operations.
Bioeconomy Capital
Company attributes
Categories
Related Topics
Contributors
- 1
Dawson Sewell
Seeking to explain science and technology through simple writing. - 2
Alex Dean
Healthcare Research Analyst @ Veradigm | Masters in Biostatistics/Epidemiology: UC Berkeley | BA in Biology: Wesleyan University - 3
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME - 4
Mevludin Mešanović
Bachelor of Electrical Engineering - 5
Jude Gomila
Founder and CEO of Golden, Entrepreneur. Investor in 200+ companies. Cantabrigian (Gonville and Caius). Interested in the universe. - 6
Will Suter
Student at the University of Notre Dame looking to expand my knowledge in topics that pique my interest. - 7
Carla Faraguna
Golden People and Operations.